Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease

Authors Steven Cheng, Daniel Coyne

Published 15 September 2006 Volume 2006:2(3) Pages 297—301

Steven Cheng, Daniel Coyne

Division of Nephrology, Washington University, School of Medicine, Saint Louis, MO, USA

Abstract: Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated, maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus for PTH secretion is a deficiency of active vitamin D. Replacement with calcitriol, the active form of vitamin D, lowers PTH but often raises calcium and phosphorus levels, predisposing patients to an increased risk of ectopic calcifications. Paricalcitol is a vitamin D analog designed to treat SHPT without raising serum calcium and phosphorus levels. The intravenous preparation of paricalcitol is used routinely in the hemodialysis population and has demonstrated a survival benefit over calcitriol in hemodialysis patients. A new oral preparation has now been developed for use in the pre-dialysis CKD population. Thus far, oral paricalcitol has been shown to reduce PTH by an average of 42% in CKD patients, while having minimal effects on serum calcium and phosphorus. While long term effects of the oral preparation have yet to be studied, emerging evidence suggests that paricalcitol mediates a variety of beneficial effects through the activation of vitamin D receptors which may result in improved survival.

Keywords: paricalcitol, secondary hyperparathyroidism, chronic kidney disease

Download Article [PDF] 

Readers of this article also read:

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Therapeutics and Clinical Risk Management 2008, 4:1305-1313

Published Date: 5 December 2008

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner, Philipp B Staber, Peter Neumeister

Therapeutics and Clinical Risk Management 2008, 4:747-757

Published Date: 8 August 2008

Optimizing medicines management: From compliance to concordance

Annie Cushing, Richard Metcalfe

Therapeutics and Clinical Risk Management 2007, 3:1047-1058

Published Date: 15 January 2008

Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model

Carin A Uyl-de Groot, Joseph McDonnell, Guul ten Velde, David Radice, Harry J M Groen

Therapeutics and Clinical Risk Management 2006, 2:317-323

Published Date: 15 September 2006

An assessment of the cost-utility of therapy for psoriasis

Stefan C Weiss, Wingfield Rehmus, Alexa B Kimball

Therapeutics and Clinical Risk Management 2006, 2:325-328

Published Date: 15 September 2006

Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease – a case series

Madeleine Nowak, Petra Büttner, Simone Harrison, Kym Daniell, Beverly Raasch, Rick Speare

Therapeutics and Clinical Risk Management 2006, 2:329-334

Published Date: 15 September 2006